Equities Analysts Offer Predictions for AXSM Q1 Earnings

Axsome Therapeutics, Inc. (NASDAQ:AXSM) – HC Wainwright cut their Q1 2026 earnings per share (EPS) estimates for shares of Axsome Therapeutics in a report issued on Wednesday, February 25th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings per share of ($0.70) for the quarter, down from their previous estimate of ($0.13). HC Wainwright has a “Buy” rating and a $260.00 price objective on the stock. The consensus estimate for Axsome Therapeutics’ current full-year earnings is ($2.79) per share. HC Wainwright also issued estimates for Axsome Therapeutics’ Q2 2026 earnings at ($0.41) EPS, Q3 2026 earnings at ($0.05) EPS, Q4 2026 earnings at $0.73 EPS, FY2026 earnings at ($0.41) EPS, Q1 2027 earnings at $1.77 EPS, Q2 2027 earnings at $2.55 EPS, Q3 2027 earnings at $3.37 EPS, Q4 2027 earnings at $4.17 EPS and FY2027 earnings at $11.87 EPS.

Axsome Therapeutics (NASDAQ:AXSM) last announced its quarterly earnings results on Monday, February 23rd. The company reported ($0.56) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.70) by $0.14. Axsome Therapeutics had a negative return on equity of 232.61% and a negative net margin of 28.69%.The firm had revenue of $196.00 million for the quarter, compared to the consensus estimate of $191.33 million. The firm’s revenue was up 65.0% on a year-over-year basis.

A number of other analysts have also commented on AXSM. Cantor Fitzgerald reiterated an “overweight” rating on shares of Axsome Therapeutics in a research note on Wednesday, January 14th. Needham & Company LLC reissued a “buy” rating and issued a $225.00 target price on shares of Axsome Therapeutics in a research report on Monday. Morgan Stanley set a $207.00 price objective on shares of Axsome Therapeutics in a research report on Tuesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Axsome Therapeutics in a report on Wednesday, January 21st. Finally, Mizuho set a $230.00 price target on Axsome Therapeutics in a report on Thursday, February 19th. Seventeen analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, Axsome Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $216.12.

Axsome Therapeutics Price Performance

NASDAQ AXSM opened at $163.19 on Friday. Axsome Therapeutics has a one year low of $86.99 and a one year high of $191.50. The stock has a 50-day moving average of $175.55 and a 200 day moving average of $145.65. The company has a debt-to-equity ratio of 1.38, a quick ratio of 1.50 and a current ratio of 1.55. The company has a market capitalization of $8.35 billion, a price-to-earnings ratio of -44.22, a PEG ratio of 34.93 and a beta of 0.40.

Institutional Trading of Axsome Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Seven Fleet Capital Management LP bought a new stake in Axsome Therapeutics during the 4th quarter valued at $2,366,000. Virtu Financial LLC purchased a new position in shares of Axsome Therapeutics during the fourth quarter valued at $2,844,000. Invesco Ltd. lifted its stake in Axsome Therapeutics by 28.6% in the fourth quarter. Invesco Ltd. now owns 1,273,494 shares of the company’s stock worth $232,591,000 after acquiring an additional 282,937 shares during the period. Strive Financial Group LLC bought a new position in Axsome Therapeutics during the 4th quarter worth about $62,000. Finally, Ameriflex Group Inc. purchased a new position in Axsome Therapeutics during the 4th quarter valued at about $37,000. 81.49% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, Director Mark E. Saad sold 37,577 shares of the stock in a transaction on Wednesday, December 31st. The stock was sold at an average price of $165.18, for a total transaction of $6,206,968.86. Following the sale, the director owned 10,002 shares in the company, valued at approximately $1,652,130.36. This represents a 78.98% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO Nick Pizzie sold 12,000 shares of the firm’s stock in a transaction on Thursday, January 22nd. The stock was sold at an average price of $187.92, for a total value of $2,255,040.00. Following the completion of the sale, the chief financial officer owned 42,588 shares of the company’s stock, valued at approximately $8,003,136.96. This represents a 21.98% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 308,874 shares of company stock worth $51,390,805. 22.30% of the stock is owned by company insiders.

Axsome Therapeutics News Roundup

Here are the key news stories impacting Axsome Therapeutics this week:

• Positive Sentiment: Wolfe Research initiated coverage with an “Outperform” rating and a $230 price target (≈41% upside vs. the $163 reference). New, bullish initiations often lift momentum and institutional interest. Wolfe Research initiation
• Positive Sentiment: HC Wainwright reaffirmed a Buy rating and a $260 target and published very bullish FY2027 EPS forecasts (FY2027 EPS = $11.87). That long‑range earnings trajectory and high target price support a higher valuation narrative for AXSM.
• Positive Sentiment: Axsome announced participation in multiple March investor conferences (TD Cowen, etc.), increasing management visibility and providing upcoming opportunities for updates and Q&A with investors. Investor conference schedule
• Positive Sentiment: Media coverage highlighting AXSM’s inclusion/performance in Nasdaq index funds and framing the stock as reaching new highs can attract momentum traders and passive flows. Kalkine article
• Neutral Sentiment: Reported short interest data for late February shows zero shares (and NaN changes) — the figures appear erroneous or not meaningful. No clear short‑sell pressure signal from these data.
• Negative Sentiment: HC Wainwright cut near‑term 2026 estimates sharply: Q1 2026 EPS from ($0.13) → ($0.70), Q2 2026 from $0.51 → ($0.41), Q3 2026 from $1.46 → ($0.05), Q4 2026 from $2.06 → $0.73, and FY2026 from $3.91 → ($0.41). Those downward revisions increase earnings uncertainty in the near term and could pressure sentiment among short‑horizon investors.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.